ACM
GPCR icon

Altium Capital Management’s Structure Therapeutics GPCR Stock Holding History

Altium Capital Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-70,000
Closed -$3.07M – 77
2024
Q3 		$3.07M Buy
+70,000
New +$2.71M 0.9% 36
2023
Q4 		– Sell
-155,000
Closed -$7.82M – 75
2023
Q3 		$7.82M Buy
+155,000
New +$5M 4.08% 9

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Altium Capital Management's GPCR Position: Q4 2024 in Review

Altium Capital Management sold out of Structure Therapeutics (GPCR) in Q4 2024, closing a stake of 70,000 shares — an estimated $3.07M sold.

Altium Capital Management first reported a position in GPCR in Q3 2023 and held it in 2 quarters. The position peaked at $7.82M in Q3 2023. 164 funds tracked by Wall St. Rank hold GPCR as of Q4 2024.

  • Altium Capital Management reported no remaining Structure Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Altium Capital Management sold 70,000 Structure Therapeutics shares in Q4 2024, an estimated $3.07M.
  • Altium Capital Management first reported a position in Structure Therapeutics in Q3 2023 and held it in 2 quarters.
  • Altium Capital Management's Structure Therapeutics position peaked at $7.82M in Q3 2023.
  • 164 funds tracked by Wall St. Rank held Structure Therapeutics as of Q4 2024.

Based on Altium Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.